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Summary
Since sperm require high energy levels to perform their specialised function, it is vital 
that essential nutrients are available for spermatozoa when they develop, capacitate 
and acquire motility. However, they are vulnerable to a lack of energy and excess 
amounts of reactive oxygen species, which can impair sperm function, lead to immotil-
ity, acrosomal reaction impairment, DNA fragmentation and cell death. This monocen-
tric, randomised, double- blind, placebo- controlled trial investigated the effect of 
6 months of supplementation with l- carnitine, acetyl- l- carnitine and other micronutri-
ents on sperm quality in 104 subjects with oligo- and/or astheno- and/or teratozoo-
spermia with or without varicocele. In 94 patients who completed the study, sperm 
concentration was significantly increased in supplemented patients compared to the 
placebo (p = .0186). Total sperm count also increased significantly (p = .0117) in the 
supplemented group as compared to the placebo group. Both, progressive and total 
motility were higher in supplemented patients (p = .0088 and p = .0120, respectively). 
Although pregnancy rate was not an endpoint of the study, of the 12 pregnancies that 
occurred during the follow-up, 10 were reported in the supplementation group. In 
general, all these changes were more evident in varicocele patients. In conclusion, 
 supplementation with metabolic and antioxidant compounds could be efficacious 
when included in strategies to improve fertility.
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1  | INTRODUCTION
Infertility is the inability of a sexually active, noncontracepting cou-
ple to achieve a spontaneous pregnancy within one year. Worldwide, 
the incidence of infertility is about 15%, of which, in general, 50% can 
be attributed to a male- associated factor. This can be reported with 
or without abnormal semen parameters (WHO, 2000). Male fertility 
can be affected by many factors ranging from congenital, endocrine, 
immunologic, infectious or lifestyle factors as well as various malig-
nancies. On the other hand, in 30%–40% of the cases, no obvious 
male infertility- associated factor is found (idiopathic male infertility; 
Nieschlag, Behre, & Nieschlag, 2010).
Varicocele is defined as an abnormal dilatation of scrotal veins, 
and various studies report a general prevalence of 15% in the healthy 
male population, whereas it is 40% in infertile men (Nagler, Luntz, & 
Martinis, 1997). Although the pathophysiologic mechanisms are not 
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yet completely known, varicocele has adverse effects on spermato-
genesis and, to date, is considered as most common among the known 
causes of male infertility (Practice Committee of American Society for 
Reproductive Medicine and the Society for Male Reproduction and 
Urology, 2014).
Since sperm functions such as capacitation and motility are all 
highly energy-dependent (Talwar & Hayatnagarkar, 2015), sper-
matozoa have very high energy requirements. Many factors that 
negatively affect semen quality act through decreasing energy avail-
ability by mitochondrial dysfunction (Amaral, Lourenço, Marques, & 
Ramalho- Santos, 2013). Spermatozoa are also vulnerable to reactive 
oxygen species (ROS) because their plasma membranes and cyto-
plasm are rich in polyunsaturated fatty acids (Agarwal et al., 2014). 
In particular, elevated ROS exposure leads to membrane damage, 
membrane instability and functional alterations causing cell death 
(Agarwal et al., 2014). Latest evidence demonstrates an associ-
ation between high ROS levels and increased mitochondrial DNA 
(mtDNA) copy number with decreased mtDNA integrity (Bonanno 
et al., 2016). Oxidative stress (OS) occurs when there is an imbalance 
between oxidants and antioxidants (Agarwal, Hamada, & Esteves, 
2012). However, for normal sperm cell function including chroma-
tin compaction in maturing spermatozoa during epididymal transit, a 
delicate redox balance between reduction and oxidation is required 
(Wright, Milne, & Leeson, 2014). In general, an oxidative milieu may 
lead to cellular degeneration by apoptosis or necrosis, and a reducing 
milieu could favour cell survival (Durackova, 2014). Thus, a thera-
peutic strategy would need to use supplements to increase sperm 
energy metabolism, minimise free radical damage to sperm and im-
prove the cellular processes connected with the formation and mat-
uration of sperm.
l- Carnitine and acetyl- l- carnitine play an important role in sper-
matozoa energy metabolism (Agarwal & Said, 2004; Zhou, Liu, & Zhai, 
2007). Many clinical studies have shown that oral administration to 
asthenozoospermic subjects increases the percentage of mobile 
spermatozoa, progressive rapid motility, average speed and linearity 
of sperm motility (Balercia et al., 2005; Lenzi et al., 2004). Selenium 
is an essential component of several major metabolic pathways: 
antioxidant defence systems, thyroid hormone metabolism and im-
mune function (Brown & Arthur, 2001). Coenzyme Q10 (CoQ10) is 
concentrated in the mitochondria located in the midpiece of sperm, 
and the levels of this compound show a significant correlation with 
sperm count and motility. Furthermore, CoQ10 may be deficient in 
varicocele leading to higher sensitivity to oxidative damage (Balercia 
et al., 2004). Fructose, citric acid, vitamin C, vitamin B12 and zinc are 
related to increased damage to the sperm genetic material, synthesis 
of coenzymes, metabolism and energy production (Chia, Ong, Chua, 
Ho, & Tay, 2000; Dawson, Harris, Teter, & Powell, 1992; Moslemi & 
Tavanbakhsh, 2011).
Thus, the objective of this trial was to evaluate sperm quality after 
supplementation of oligo- and/or astheno- and or teratozoospermic 
subjects with or without varicocele with selected naturally occurring 
antioxidative compounds in a randomised, double-blind, placebo-con-
trolled setting.
2  | MATERIALS AND METHODS
Between December 2014 and June 2015, 104 infertile patients with 
oligo- and/or astheno- and/or teratozoospermia with an average 
age of 32.5 years (range 18–48) were enrolled in this single- centre, 
randomised, double- blind, placebo- controlled trial to determine the 
effect of antioxidant supplementation on semen quality. All partici-
pants were enrolled from our Andrology Clinic at the Department of 
Gynecological- Obstetric Sciences and Urological Sciences, “Sapienza” 
Rome University. The block randomisation method was used to ran-
domise subjects into groups resulting in equal sample sizes to ensure 
a balance across the groups over time. At the commencement of the 
study, 52 patients with varicocele grade I- III (confirmed with Doppler 
ultrasound) and 52 patients without varicocele were divided into two 
groups each consisting of the supplementation and a placebo sub-
group. Ten patients dropped out from the study leaving 45 patients 
with varicocele and 49 without varicocele.
The supplementation formulation (Proxeed Plus from Sigma- 
Tau HealthScience, Utrecht, the Netherlands) consisted of 1,000 mg 
l- carnitine, 725 mg fumarate, 500 mg acetyl- l- carnitine, 1,000 mg fruc-
tose, 20 mg CoQ10, 90 mg vitamin C, 10 mg zinc, 200 μg folic acid and 
1.5 μg vitamin B12. The placebo was provided from the same company 
and was made with excipients (sucrose, silica (anti- caking), lemon fla-
vour, acesulfame K (E950) sweetener) of the supplementation without 
the active compounds.
Subjects received supplements or placebo (two sachets daily for 
6 months) according to the randomisation schedule (nQuery Advisor 
nTerim 2.0 (2012) program) and were instructed of the method of use. 
One evaluation of a spermiogram was carried out at the beginning of 
the treatment (V1) to examine semen parameters in each patient. At 
the end of the 6- month treatment (V2), a consecutive semen sample 
was collected. Together with the semen analyses, before and after the 
treatment, we collected demographic data (age, weight, height), phys-
ical examination, blood pressure, medical history and intake of previ-
ous/concomitant therapies.
Semen samples were collected after 3–5 days of sexual absti-
nence. Ejaculate volume, total sperm count, total and progressive mo-
tility, as well as normal sperm morphology were evaluated according 
to WHO guidelines (2010; 5th edition guidelines).
Subjects included in our trial were men between 18 and 50 
years of age with oligo- , astheno- and/or teratozoospermia, with or 
without varicocele, and having a history of infertility for more than 
12 months. The varicocele patients were not surgically treated be-
fore and during the treatment. Patients without varicocele were suf-
fering from idiopathic male infertility, and no other previous history 
of diseases affecting fertility. Every patient underwent a complete 
check- up to exclude any other cause of infertility (history, examina-
tion, complete ultrasound and Doppler, hormones and genetic tests) 
with no difference between varicocele and nonvaricocele patients. 
Fertile female partners were required with regular menstrual cycles, 
age <40 and couples not looking for fertility- related procedures such 
as in vitro fertilization (IVF) or artificial insemination (AI), or intracy-
toplasmic sperm injection (ICSI) for the next 90 days.
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Subjects with known hypersensitivity to any of the treatment 
compounds, history of undescended testes or cancer, endocrine 
disorders, history of post- pubertal mumps, genitourinary surgery, 
obstructive azoospermia or obstructive pathology of the urogenital 
system, autoimmune disease, cystic fibrosis, history of taking any 
therapy affecting fertility within last 3 months, excessive consump-
tion of alcohol or regular use of illicit or “recreational” drugs, positive 
serology for HIV, subjects following any special diet, any condition 
which in the opinion of the investigator might put the subject at risk 
by participating in this study and subjects involved in any other clin-
ical trials were excluded from the trial. Endpoints of the study were 
sperm concentration, semen volume, total sperm count, total motil-
ity, progressive motility and percentage of normal sperm morphology.
The Ethical Committee of the Department of Gynecological- 
Obstetric Sciences and Urological Sciences, “Sapienza” Rome 
University, approved the study protocol (Institute Ethical Approval 
Number PXP- 001A). The study was conducted in line with European 
Urology and Good Clinical Practice guidelines, with ethical principles 
laid down in the latest version of the Declaration of Helsinki. Every 
patient signed an informed consent to participate in the study.
2.1 | Sample size
Planning to carry out the analysis of covariance in a factorial design 
with two groups (Proxeed or Placebo, with and without varicocele), de-
fined f = σm/σ = 0.25, a correlation coefficient (R2) between the base-
line and final equal to 0.50, an α = .05 (significance) and β = .20 (power 
of 80%), made it necessary that at least 88 patients equally distributed 
in 22 units for each subgroup had to be enrolled. However, in anticipa-
tion of having about 15% of dropout, 104 patients (52 per arm) were 
enrolled.
2.2 | Statistical analysis
All continuous variables have been reported as mean, median, stand-
ard deviations, minimum and maximum values. Discrete and nominal 
variables have been reported as frequency and percentage in contin-
gency tables. The basal homogeneity of groups has been tested, on 
the continuous variables, by the analysis of variance (ANOVA) with 
two levels (drug and varicocele). The Shapiro–Wilk test was adopted 
for checking the normal distribution of the data. In the present analy-
sis, no discrete variables were considered for testing the homogeneity 
of groups.
All the study endpoints considered in the present analysis were 
evaluated, on the complete sample, by the analysis of covariance for a 
model with two classification levels. The independent variable was the 
value detected at the baseline visit, while the dependent variable was 
the value detected at the end of treatment. The Wilcoxon rank- sum 
test was adopted for comparing the two groups at baseline, while the 
Wilcoxon signed rank test was used in the comparisons before/after 
by group. A “Responder,” was defined as, a patient whose parameters 
improved in comparison to the values before the treatment at the 
final visit. A responder analysis was also carried out. The Chi- squared 
test was adopted for detecting possible differences between the two 
treatment groups. All the above analyses (apart from the ANCOVA) 
were repeated for the comparison of the two groups separately by 
the presence of varicocele. Considering the low power, due to the 
small size, the responses of the tests presented separately for the 
presence of the varicocele have to be evaluated accordingly. SAS® 
Vers. 9.4 was used for performing all the analyses.
3  | RESULTS
In total, 94 (of 104) patients completed the study. Table 1 summa-
rises demographic and baseline characteristics of the population 
by treatment group. The results of the homogeneity tests show 
that the two groups were well- balanced. The descriptive analyses 
show that at baseline, all sperm parameters in patients suffering 
from varicocele were lower when compared to the non-varicocele 
group.
Adverse events (Table 2) that did not lead to stop the therapy, 
 occurred only in the treatment group. All events were not serious: four 
patients had nausea and three vertigo or headache.
The results of the inferential analyses of the semen parameters 
are presented in Table 3. As for the ANCOVA, the p- values refer to 
the intention- to- treat population (ITT). The last observation carried 
forward (LOCF) method was used for replacing the missing data. 
The analyses are also presented for varicocele patients (Table 4) and 
non-varicocele patients (Table 5). The Wilcoxon rank- sum test was 
adopted for calculating the p- values. In analyzing the comparisons 
before/after in the placebo group, a significant difference in some 
parameters was observed. Therefore, the results of all the tests were 
also included in both the tables and the text. The responder analysis 
for all the parameters was carried out for all the groups and included 
in Table 6.
3.1 | Sperm concentration
The overall results for the sperm concentration in all subjects are 
summarised in Table 3. In the placebo group, sperm concentra-
tion was 41.4 ± 17.9 × 106/ml at baseline and 43.7 ± 13.6 × 106/
ml at the final visit. In the supplemented group, sperm concentra-
tion was 40.8 ± 18.2 × 106/ml at baseline and 51.4 ± 13.9 × 106/ml 
at final visit. While for the placebo group no change was observed 
(p = .5244), the increase in sperm concentration for the treatment 
group was significant (p = .0026). Before the treatment, the sperm 
concentration in the placebo group did not differ from that in the 
treatment group (p = .8453). At the end of the trial, the difference 
between both groups was significant (p = .0186) in favour of the 
supplemented group.
In varicocele patients (Table 4), the mean sperm concentra-
tions in the placebo group was 38.7 ± 18.1 × 106/ml at baseline and 
39.9 ± 17.2 × 106/ml at the final visit (p = .7572). In the supplemented 
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group, sperm concentration significantly (p = .0403) increased from 
38.5 ± 19.0 × 106/ml at baseline to 50.2 ± 17.9 × 106/ml at the final 
visit. Before the treatment, the placebo and treatment groups showed 
no difference (p = .9708). The comparison of the changes from base-
line baseline between the two groups showed nonsignificant differ-
ence (p = .1391) in favour of the supplemented group.
The results of sperm concentration at baseline in non-varico-
cele patients (Table 5) in the placebo group were 44.1 ± 17.5 × 106/
ml and 47.2 ± 7.8 × 106/ml at the final visit (p = .5318). In 
the supplemented group a mean sperm concentration of 
43.2 ± 17.3 × 106/ml was found at baseline and of 52.5 ± 9.4 × 106/
ml at the final visit (p = .0354). Before the treatment, the placebo and 
treatment groups showed no difference (p = .8048). The comparison 
of the changes from baseline between the two groups showed no 
difference (p = .2460) in favour of the supplemented group.
The responder analysis (Table 6) showed that 73.3% of supple-
mented patients versus 51.0% of the patients in the placebo group 
increased from baseline (p = .0262).
Parameter Statistics Placebo Supplemented Total
Age (years) N 52 52 104
Missing 0 0 0
Mean 32.5 32.5 32.5 (p = .9792)
Std. Deviation 6.7 6.7 6.7
Median 33.0 32.0 32.3
Range 19.0–48.6 18.8–48.4 18.8–48.6
Height (cm) N 52 52 104
Missing 0 0 0
Mean 178.6 177.2 177.9 (p = .2487)
Std. Deviation 6.0 6.0 6.0
Median 180.0 177.0 178.0
Range 168.0–190.0 163.0–192.0 163.0–192.0
Weight (kg) N 52 52 104
Missing 0 0 0
Mean 76.4 75.1 75.8 (p = .4242)
Std. Deviation 8.7 7.7 8.2
Median 75.0 75.0 75.0
Range 62.0–94.0 62.0–93.0 62.0–94.0
HR (b/min) N 52 52 104
Missing 0 0 0
Mean 70.8 70.4 70.6 (p = .6295)
Std. Deviation 4.5 3.5 4.0
Median 70.0 70.0 70.0
Range 60–80 60–78 60–80
SBP (mmHg) N 52 52 104
Missing 0 0 0
Mean 119.4 117.2 118.3 (p = .0961)
Std. Deviation 7.3 6.3 6.9
Median 120.0 120.0 120.0
Range 100–130 110–130 100–130
DBP (mmHg) N 52 52 104
Missing 0 0 0
Mean 72.4 73.2 72.8 (p = .4707)
Std. Deviation 5.8 5.5 5.7
Median 70.0 70.0 70.0
Range 60–90 60–85 60–90
Results from ANOVA with two levels (drug and varicocele).
TABLE  1 Baseline characteristics
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3.2 | Semen volume
Overall results for the semen volume are summarised in Table 3. 
While the mean semen volume in the placebo group was 3.0 ± 1.0 ml 
at baseline, it was 2.9 ± 1.0 ml at the final visit. In the supplemented 
group, 3.1 ± 1.2 ml were ejaculated at baseline and 3.2 ± 0.9 ml 
at the final visit. In both groups, placebo and treatment group, no 
changes (p = .6787) and (p = .6271) were observed. There were also 
no differences for the comparison between the two groups at base-
line (p = .7499) and at the final visit (p = .1313).
In varicocele patients (Table 4), the mean semen volume at base-
line in the placebo group was 2.7 ± 0.7 ml and 2.4 ± 1.1 ml after the 
treatment. In the treatment group, semen volume was 2.9 ± 1.2 ml 
at baseline and 3.2 ± 1.2 ml at the final visit. No difference before/
after was observed in both the placebo (p = .2250) and the supple-
mented group (p = .3632). Comparing the two groups at baseline 
(p = .8761) and at the end of the study showed also no difference 
(p = .1273).
As for non-varicocele patients (Table 5), the semen volume in 
the placebo group was 3.2 ± 1.1 ml before and 3.3 ± 0.8 ml after the 
treatment. In the supplemented group it was 3.4 ± 1.2 ml at baseline 
and 3.3 ± 0.6 ml at the final visit. Furthermore, for non-varicocele 
patients, no difference before/after was observed in both the placebo 
group (p = .7711) and the supplemented group (p = .8753). The data 
at baseline (p = .6144) and at the end of the study (p = .5026) also did 
not differ.
The responder analysis (Table 6) did not show a difference be-
tween the two groups; 48.9% of supplemented patients versus 
46.9% in the placebo group were considered as responders at final 
visit (p = .8500).
3.3 | Total sperm count
The overall results for the total sperm count in all subjects are 
summarised in Table 3. In the placebo group, 113.1 ± 37.4 × 106 
at baseline and 127.8 ± 61.4 × 106 at the final visit, while the total 
sperm count in the supplemented group, was 114.2 ± 37.8 × 106 at 
baseline and 163.5 ± 64.3 × 106 at the final visit. While for the pla-
cebo group no change was observed (p = .2030), the increase in the 
supplemented group was highly significant (p < .0001). In contrast, 
no difference (p = .8658) was observed between the two groups at 
baseline. At the end of the study, the two groups differed in fa-
vour of the supplemented group as was confirmed by the inferential 
analysis with p = .0117.
In the varicocele group (Table 4), total sperm count in the placebo 
was 100.5 ± 41.9 × 106 at baseline and 102.4 ± 77.2 × 106 at the 
final visit (p = .5749). The supplemented group had a sperm concen-
tration of 96.3 ± 36.1 × 106 at baseline and of 158.8 ± 90.1 × 106 at 
the final visit (p = .0009). While both groups did not differ at baseline 
(p = .8764), the values in the supplemented group were significantly 
higher at the final visit (p = .0066).
In non-varicocele patients (Table 5), the total sperm count for the 
group was 125.6 ± 27.7 × 106 at baseline and 152.1 ± 23.9 × 106 after 
the treatment (p = .0022) and increased significantly (p = .0005), from 
132.0 ± 30.9 × 106 at baseline to 167.6 ± 28.5 × 106 at final visit in 
the supplemented groups. No significant difference between the two 
groups was observed at baseline (p = .4259) and final visit (p = .2460).
The responder analysis (Table 6) showed that 82.2% of supple-
mented patients versus 55.1% in the placebo group increased from 
baseline (p = .0048).
3.4 | Progressive motility
For the progressive motility, the overall results are summarised in 
Table 3. In the placebo group, progressive motility was 23.0 ± 7.8% 
at baseline and 24.5 ± 7.2% at the final visit (p = .1567), while it was 
23.4 ± 6.1% and 28.6 ± 8.2% at baseline final visit (p = .0012). The 
two groups did not differ (p = .6701), before the treatment. However, 
at the end of the study, a significant (p = .0088) difference in favour of 
the supplemented group was observed.
In varicocele patients (Table 4), progressive motility was 
21.8 ± 6.2% at baseline and 23.6 ± 6.8% at the final visit in the pla-
cebo group (p = .1570) while it was 23.1 ± 5.2% and 27.4 ± 7.2%, 
respectively visit in the treated group (p = .0149). No difference be-
tween the two groups was observed at baseline (p = .3096) and at 
study end (p = .1686).
In the non-varicocele group (Table 5), progressive motility was 
24.2 ± 9.1% before and 25.4 ± 7.7% after treatment in the placebo 
arm (p = .4866) and 23.7 ± 7.0% at baseline and 29.6 ± 9.0% at the 
final visit in the treatment arm (p = .0311). Also for this comparison, 
TABLE  2 Listing of adverse events
Treatment group Id. no. Age Description (PT term) Seriousness Relationship Action taken
Supplemented 36 32 Nausea Not serious Probable None
Gastro- oesophageal reflux disease Not serious Probable None
67 27 Nausea Not serious Possible None
Vertigo Not serious Possible None
68 21 Headache Not serious Possible None
Nausea Not serious Possible None
85 28 Headache Not serious Possible None
Nausea Not serious Possible None
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the test was not statistically significant for both baseline (p = .8907) 
and final visit (p = .2040).
The responder analysis (Table 6) showed that 73.3% of supple-
mented patients responded to the treatment whereas it was only 
51.0% in the placebo group (p = .0262).
3.5 | Total motility
The summary results for total motility are depicted in Table 3. In the pla-
cebo group, the means were 32.6 ± 9.2% before and 34.6 ± 7.1% after 
the treatment (p = .1483). In the supplemented group, baseline and 
TABLE  3 Sperm parameters. Absolute values of baseline and final
Parameter Groups Statistics Baseline Final
p- Values 
before/after**
Sperm concentration (106 ml) Placebo N 52 49
Missing 0 3
Mean 41.4 43.7 .5244
Std. Deviation 17.9 13.6
Median 38.3 44.0
Range 11.0; 79.0 16.0; 79.0
Supplemented N 52 45
Missing 0 7
Mean 40.8 51.4 .0026
Std. Deviation 18.2 13.9
Median 39.0 49.0
Range 12.3; 77.0 28.0; 86.0
p- Values by visit* .8453 .0186
Volume of ejaculate (ml) Placebo N 52 49
Missing 0 3
Mean 3.0 2.9 .6787
Std. Deviation 1.0 1.0
Median 2.8 3.0
Range 1.3; 6.3 1.1; 5.1
Supplemented N 52 45
Missing 0 7
Mean 3.1 3.2 .6271
Std. Deviation 1.2 0.9
Median 2.8 3.2
Range 1.4; 6.0 1.1; 5.5
p- Values by visit* .7499 .1313
Total sperm count (106) Placebo N 52 49
Missing 0 3
Mean 113.1 127.8 .2030
Std. Deviation 37.4 61.4
Median 107.6 136.7
Range 30.0; 197.6 24.0; 270.0
Supplemented N 52 45
Missing 0 7
Mean 114.2 163.5 <.0001
Std. Deviation 37.8 64.3
Median 112.1 158.4
Range 43.2; 205.8 48.4; 369.6
p- Values by visit* .8658 .0117
(Continues)
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values obtained at the final visit differed significantly (p < .0001). While 
the two groups were balanced at baseline (p = .5239), a significant (p = 
.0120) difference between the two groups at the end of the treatment 
was evident in favour of the supplemented group.
In varicocele patients (Table 4), total sperm motility in subjects 
who received the placebo did not change from baseline to the final 
visit (p = .1214). However, in the treated group, values increased from 
31.5 ± 8.1% at baseline to 37.5 ± 7.1% after the treatment (p = .0065). 
Parameter Groups Statistics Baseline Final
p- Values 
before/after**
Progressive motility (%) Placebo N 52 49
Missing 0 3
Mean 23.0 24.5 .1567
Std. Deviation 7.8 7.2
Median 22.3 23.0
Range 5.9; 43.2 8.1; 44.0
Supplemented N 52 45
Missing 0 7
Mean 23.4 28.6 .0012
Std. Deviation 6.1 8.2
Median 23.2 27.0
Range 12.0; 40.0 15.0; 57.9
p- Values by visit* .6701 .0088
Total motility (%) Placebo N 52 49
Missing 0 3
Mean 32.6 34.6 .1483
Std. Deviation 9.2 7.1
Median 32.0 35.0
Range 8.0; 55.0 12.0; 49.2
Supplemented N 52 45
Missing 0 7
Mean 31.7 39.0 <.0001
Std. Deviation 8.2 8.0
Median 31.3 37.5
Range 18.9; 48.0 29.0; 65.3
p- Values by visit* .5239 .0120
Sperm morphology—typical (%) Placebo N 52 49
Missing 0 3
Mean 21.1 15.7 .0146
Std. Deviation 16.2 9.4
Median 15.0 15.0
Range 3.0; 59.0 3.0; 52.0
Supplemented N 52 44
Missing 0 8
Mean 23.5 17.7 .0055
Std. Deviation 14.6 15.2
Median 20.0 13.5
Range 5.0; 64.0 3.0; 77.0
p- Values by visit* .2062 .3791
TABLE  3  (Continued)
(Continues)
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Yet, no difference was observed at baseline (p = .7836) and at the end 
of the study (p = .3164).
As for the non-varicocele group (Table 5), total motility was 
33.9 ± 10.2% before and 34.7 ± 7.5% after the treatment in the pla-
cebo group (p = .5604) and 31.8 ± 8.4% and 40.2 ± 8.7% at baseline 
and final visit respectively, in the treated group (p = .0028). Both 
groups were balanced at baseline (p = .5396). However a statistical dif-
ference in favour of the supplemented group was evident (p = .0257).
The responder analysis (Table 6) showed that 68.9% of supple-
mented patients versus 53.1% in the placebo group increased from 
baseline (p = .1166).
3.6 | Normal sperm morphology
Analyzing sperm morphology (Table 3), results indicate that in the pla-
cebo group 21.1 ± 16.2% sperm at baseline and 15.7 ± 9.4% sperm 
after the treatment (p = .0146) has normal morphology. In the treat-
ment group, normal sperm morphology was 23.5 ± 14.6% before and 
17.7 ± 15.2% after the (p = .0055) treatment. No difference between 
the two groups was observed at baseline (p = .2062) and at study end 
(p = .3791).
Looking at atypical morphology (Table 3) the placebo group 
showed significantly (p = .0105) higher values at the final visit, while 
baseline and final values in the supplemented group did not differ 
(p = .1310). Further, two groups did not differ at baseline (p = .5379) 
and at the end of study (p = .5081).
3.7 | Pregnancy rate
Twelve pregnancies occurred during the follow- up time: 10 in the 
supplementation group (nine non-varicocele and one varicocele) and 
two in the placebo group (one non-varicocele and one varicocele). 
One spontaneous abortion was reported in the placebo arm.
4  | DISCUSSION
Male infertility is a medical condition and a relevant social problem 
that has a strong impact on well- being. From various studies, it has 
emerged that seminal oxidative stress and sperm DNA damage must 
be taken into account as critical factors in the aetiology of semen al-
terations and infertility (Saalu, 2010; Vessey et al., 2016).
When levels of free radicals, and in particular ROS, are in-
creased and antioxidant levels are decreased, OS occurs (Agarwal, 
Roychoudhury, Bjugstad, & Chou, 2016). OS has negative effects on 
sperm quality parameters and was shown to impact the DNA carried 
by these specialised cells. Human mitochondrial DNA gene alterations 
were associated with many pathological conditions, and this damage 
per se is also a recognized cause of poor sperm quality. Thus, target-
ing OS is a strategy to increase fertility and spermatozoa number and 
quality (Agarwal et al., 2016).
Varicocele is associated with an increase in ROS production and 
seminal OS leading to sperm dysfunction. Mitochondria are a key 
source of ROS production especially when they are damaged or dys-
functional due to lack of proper substrates and cofactors. In addition, 
mitochondrial gene mutations can also affect the respiratory electron 
transfer chain. These DNA variants probably underlie mitochondrial 
dysfunction leading to impaired ATP synthesis and ultimately interfere 
with sperm motility and fertility status (Heidari et al., 2016).
Non-enzymatic antioxidants including vitamins (mainly vitamins 
A, B, C, E), glutathione as well as metabolic coenzymes such as pan-
tothenic acid, Co Q10, carnitines (l- carnitine and acetyl-l-carnitine) 
Parameter Groups Statistics Baseline Final
p- Values 
before/after**
Sperm morphology—atypical (%) Placebo N 52 49
Missing 0 3
Mean 78.9 84.1 .0105
Std. Deviation 15.4 9.3
Median 82.5 85.0
Range 41.0; 97.0 48.0; 97.0
Supplemented N 52 45
Missing 0 7
Mean 80.2 82.5 .1310
Std. Deviation 16.6 15.2
Median 85.0 86.0
Range 22.0; 96.0 23.0; 100.0
p- Values by visit* .5379 .5081
*The p- values for the Baseline visit are derived from the comparison between the two groups with the Wilcoxon rank- sum test. The p- values for the final 
visit are derived from the ANCOVA on the ITT population.
**The p- values before/after by treatment group are derived from the Wilcoxon signed rank test.
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and micronutrients (zinc, selenium, copper) are often deficient , hence 
causing a general diminution in the antioxidant status as well as mi-
tochondrial dysfunction (Jeulin & Lewin, 1996; Virmani, Ali, Pinto, 
Zerelli, & Binienda, 2016). Nutrients such as zinc, folic acid, vitamin 
B12, l- carnitine and acetyl- l- carnitine are also associated with sperm 
production and maturation (Adams et al., 1998; Ebisch, Thomas, 
Peters, Braat, & Steegers- Theunissen, 2007; Jeulin & Lewin, 1996; 
Watanabe et al., 2003).
Studies demonstrate that using these substances has a beneficial 
effect on fertility, in particular on sperm quality and are therefore 
TABLE  4 Sperm parameters. Patients with varicocele. Absolute values of baseline and final visits
Parameter Groups Statistics Baseline Final
p- Values 
before/after**
Sperm concentration (106 ml) Placebo N 26 24
Missing 0 2
Mean 38.7 39.9 .7572
Std. Deviation 18.1 17.2
Median 32.0 34.8
Range 17.5; 76.0 16.0; 79.0
Supplemented N 26 21
Missing 0 5
Mean 38.5 50.2 .0403
Std. Deviation 19.0 17.9
Median 32.5 45.0
Range 12.3; 76.0 28.0; 86.0
p- Values by visit* .9708 .1391
Volume of ejaculate (ml) Placebo N 26 24
Missing 0 2
Mean 2.7 2.4 .2250
Std. Deviation 0.7 1.1
Median 2.7 2.2
Range 1.3; 4.1 1.1; 5.0
Supplemented N 26 21
Missing 0 5
Mean 2.9 3.2 .3632
Std. Deviation 1.2 1.2
Median 2.6 3.2
Range 1.4; 5.6 1.1; 5.5
p- Values by visit* .8761 .1273
Total sperm count (106) Placebo N 26 24
Missing 0 2
Mean 100.5 102.4 .5749
Std. Deviation 41.9 77.2
Median 94.9 77.7
Range 30.0; 197.6 24.0; 270.0
Supplemented N 26 21
Missing 0 5
Mean 96.3 158.8 .0009
Std. Deviation 36.1 90.1
Median 96.1 126.0
Range 43.2; 190.6 48.4; 369.6
p- Values by visit* .8764 .0066
(Continues)
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recommended as potentially effective therapy for the treatment 
of male infertility (Walczak- Jedrzejowska, Wolski, & Slowikowska- 
Hilczer, 2013).
l- Carnitine together with acetyl- l- carnitine is a safe treatment 
commonly used because of their capacity in improving sperm quality 
and pregnancy rate in males suffering from astheno- teratozoospermia 
(Wang et al., 2010). Selenium is essential for testis development, 
spermatogenesis and final sperm quality. It acts via a positive anti-
oxidant action through glutathione peroxidase enzymes (Moslemi & 
Tavanbakhsh, 2011). Both vitamin E and zinc play a role in antioxi-
dant balance regulation and are able to improve sperm concentration, 
percentage of progressively motile sperm and consequently preg-
nancy rate (Ajina, Sallem, Haouas, & Mehdi, 2016; Chen et al., 2012). 
Coenzyme Q10 levels show a significant correlation with sperm count 
and with sperm motility (Festa et al., 2014; Mancini et al., 1994). 
Administration of coenzyme Q10 to men with idiopathic asthenozoo-
spermia results in an increase in sperm motility (Balercia et al., 2004).
The real association between varicocele and fertility status is 
still not completely clarified, but a recent meta- analysis showed 
a significant improvement in semen parameters in patients after 
varicocelectomy (Agarwal et al., 2007). Furthermore, after surgical 
treatment, a reversal in the sperm DNA damage was evidenced (Zini 
& Dohle, 2011). Gual- Frau et al. (2015) confirmed a beneficial ef-
fect of antioxidant compounds in patients suffering from grade I 
varicocele. In their study, patients showed an average relative re-
duction of 22.1% in sperm DNA fragmentation (p = .02) with 31.3% 
fewer highly degraded sperm cells (p = .07). The total number of 
sperm was also significantly increased after 3 months of treatment. 
Another recent trial conducted on patients with high- grade varico-
cele, and randomised for surgical treatment or l- carnitine supple-
mentation, reported good results in all sperm parameters: motility 
changed from 21.7% to 35.4% (vs. 33.9%–47.5% in l- carnitine 
group), normal sperm morphology changed from 46.3% to 60% (vs. 
56.6%–69.7% in the l-carnitine group) and seminal volume changed 
Parameter Groups Statistics Baseline Final
p- Values 
before/after**
Progressive motility (%) Placebo N 26 24
Missing 0 2
Mean 21.8 23.6 .1570
Std. Deviation 6.2 6.8
Median 22.3 22.0
Range 10.0; 40.0 15.0; 44.0
Supplemented N 26 21
Missing 0 5
Mean 23.1 27.4 .0149
Std. Deviation 5.2 7.2
Median 23.4 27.0
Range 13.0; 33.3 15.0; 41.7
p- Values by visit* .3096 .1686
Total motility (%) Placebo N 26 24
Missing 0 2
Mean 31.3 34.5 .1214
Std. Deviation 8.2 6.9
Median 31.5 35.0
Range 8.0; 45.0 18.0; 49.0
Supplemented N 26 21
Missing 0 5
Mean 31.5 37.5 .0065
Std. Deviation 8.1 7.1
Median 30.4 36.0
Range 21.0; 46.7 29.0; 55.0
p- Values by visit* .7836 .3164
*The p- values for the Baseline visit are derived from the comparison between the actual baseline values of the two groups with the Wilcoxon rank- sum test. 
The p- values for the final visit are derived from the comparison on the differences before/after between the two groups with the Wilcoxon rank- sum test.
**The p- values before/after by treatment group are derived from the Wilcoxon signed rank test.
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from 3.5 to 4.2 ml (vs. 2.9–4.3 ml in the l- carnitine group). The au-
thors concluded that supplementary treatment was as effective as 
varicocelectomy in improving semen parameters and can therefore 
be used as an alternative to surgery (Sofimajidpour, Ghaderi, & 
Ganji, 2016).
Lastly, in a Cochrane analysis, men taking oral dietary supplemen-
tation for infertility were able to obtain better live birth rates in couples 
undergoing assisted reproductive techniques (Showell et al., 2014).
Comparing the effectiveness of varicocelectomy and medical 
therapy to treat these cases of infertility is difficult, and trials are 
TABLE  5 Sperm parameters. Patients without varicocele. Absolute values of baseline and final visits
Parameter Groups Statistics Baseline Final
p- Values 
before/after**
Sperm concentration (106 ml) Placebo N 26 25
Missing 0 1
Mean 44.1 47.2 .5318
Std. Deviation 17.5 7.8
Median 42.3 48.5
Range 11.0; 79.0 30.0; 65.0
Supplemented N 26 24
Missing 0 2
Mean 43.2 52.5 .0354
Std. Deviation 17.3 9.4
Median 42.4 50.5
Range 19.0; 77.0 37.7; 78.0
p- Values by visit* .8048 .2460
Volume of ejaculate(ml) Placebo N 26 25
Missing 0 1
Mean 3.2 3.3 .7711
Std. Deviation 1.1 0.8
Median 3.0 3.1
Range 1.5; 6.3 2.0; 5.1
Supplemented N 26 24
Missing 0 2
Mean 3.4 3.3 .8753
Std. Deviation 1.2 0.6
Median 3.3 3.2
Range 1.9; 6.0 2.0; 4.5
p- Values by visit* .6144 .5026
Total sperm count (106) Placebo N 26 25
Missing 0 1
Mean 125.6 152.1 .0022
Std. Deviation 27.7 23.9
Median 118.0 154.0
Range 69.3; 178.6 107.5; 200.9
Supplemented N 26 24
Missing 0 2
Mean 132.0 167.6 .0005
Std. Deviation 30.9 28.5
Median 132.2 163.8
Range 68.4; 205.8 107.5; 220.8
p- Values by visit* .4259 .2460
(Continues)
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limited by small case studies and non-randomisation. There is only 
one report with a direct comparison between l- carnitine and var-
icocelectomy in patients with grade II/III varicocele. The authors 
describe a statistically significant improvement in sperm count, mo-
tility and morphology after treatment, and results are not different 
between different treatment methods. The main limitations of the 
study are the inclusion criteria, small sample size. In addition, this 
study is not a randomized, double- blind placebo- controlled (DBPC) 
study (Sofimajidpour et al., 2016).
Our trial evaluated the utilisation of a combination of metabolic 
substances, antioxidants and micronutrients to improve sperm pa-
rameters. For a better understanding of the action of the supple-
mentation, we applied a DBPC system and very specific inclusion 
and exclusion criteria. Furthermore, in consideration of the still not 
clear effect of varicocele on male fertility, we divided our cohort into 
infertile varicocele patients and idiopathic infertile non-varicocele 
patients. At the end of the trial, we observed a marked increase in 
sperm count and concentration together with increases in motility, 
progressive motility and morphology. All differences between treat-
ment and placebo groups were statistically significant in both varico-
cele and non-varicocele patients. A small difference (not statistically 
significant) was also observed in the semen volume in favour of the 
experimental group. In general, differences were more evident in 
those patients suffering from varicocele, which can probably be ex-
plained with the major OS and ROS- mediated damage that is usually 
associated with this condition. Unfortunately, at the moment, it is not 
possible to conclude whether the medical treatment is inferior or su-
perior to varicocelectomy in those men with varicocele. Affirmation 
whether or not oral supplementation can replace surgery has yet to 
be properly established. Nevertheless, it is important to take into 
consideration that the role of oral supplements in clinical practice in 
the two groups is completely different, and one could possibly rather 
speak about an association between surgery and oral supplementa-
tion be more appropriate.
Parameter Groups Statistics Baseline Final
p- Values 
before/after**
Progressive motility (%) Placebo N 26 25
Missing 0 1
Mean 24.2 25.4 .4866
Std. Deviation 9.1 7.7
Median 23.9 25.0
Range 5.9; 43.2 8.1; 40.0
Supplemented N 26 24
Missing 0 2
Mean 23.7 29.6 .0311
Std. Deviation 7.0 9.0
Median 23.2 27.5
Range 12.0; 40.0 15.0; 57.9
p- Values by visit* .8907 .2040
Total motility (%) Placebo N 26 25
Missing 0 1
Mean 33.9 34.7 .5604
Std. Deviation 10.2 7.5
Median 32.0 35.0
Range 15.5; 55.0 12.0; 49.2
Supplemented N 26 24
Missing 0 2
Mean 31.8 40.2 .0028
Std. Deviation 8.4 8.7
Median 31.4 37.8
Range 18.9; 48.0 29.0; 65.3
p- Values by visit* .5396 .0257
*The p- values for the Baseline visit are derived from the comparison between the actual baseline values of the two groups with the Wilcoxon rank- sum test. 
The p- values for the final visit are derived from the comparison on the differences before/after between the two groups with the Wilcoxon rank- sum test.
**The p- values before/after by treatment group are derived from the Wilcoxon signed rank test.
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Although pregnancy rate was not an endpoint of the study, it is 
interesting to note that of the 12 pregnancies that occurred during 
the follow-up time, 10 were reported in the supplementation group.
The safety of the formulation was assured by its composition, 
and tolerability was confirmed by the almost total absence of adverse 
effects during the treatment. We did not compare the effect of this 
treatment with surgical treatment of varicocele, and we did not eval-
uate DNA fragmentation and the levels of ROS. Furthermore, latest 
evidences revealed that evaluating OS can be a diagnostic tool in pre-
dicting the best responders to supplementation (Vessey et al., 2016). 
Oxidative stress is a cause of male infertility with significant negative 
effect on semen parameters, and varicocele is not only causing OS, but 
also an additional cause of poor sperm quality. The use of carnitines 
and other functional substances can form part of an efficacious strat-
egy to manage and treat male infertility in both non-varicocele and 
varicocele subjects. Indeed, we plan future studies to examine the role 
of energy metabolism, OS and ROS in particular to gain a better under-
standing of underlying mechanisms and thereby to determine the best 
strategies for male infertility treatment.
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